ASX
LCT 0.088    Last updated 9.40 am
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

Cell therapy for neurodegenerative diseases

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

 

Our lead product, NTCELL®, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory, producing factors to promote new central nervous system growth and repair disease-induced nerve degeneration.

 

A Phase IIb trial of NTCELL for Parkinson's disease is currently underway. It aims to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. If the trial is successful LCT will apply for provisional consent to treat paying patients in New Zealand and launch NTCELL as the first disease modifying treatment for Parkinson’s disease, in 2017.

 

In addition to Parkinson’s disease, NTCELL has the potential to be used in a number of other central nervous system indications, including Huntington’s, Alzheimer’s and motor neurone diseases including amyotrophic lateral sclerosis (ALS).

 

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

 

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges and is incorporated in Australia, with operations based in New Zealand.

— 24 August 2016

Preliminary Final Report

The Preliminary Final Report (Appendix 4E) on the results for the year ended 30 June 2016 is attached. The net loss for the financial year to 30 June 2016 was $3,093,163 compared to a loss of $7,043,402 in the prior year. The decreased loss was primarily due to markedly reduced share of the joint venture loss as the carrying value of the investment has been reduced to zero. The end of year cash balance was $5,301,999 compared to $5,144,027 last year due to the $3.7m raised in the private placements and share purchase plan, partially offset by clinical trial and operating costs.

Read More Read Less

— 22 August 2016

LCT’s joint venture focuses on US development

50% owned joint venture company Diatranz Otsuka Limited (DOL) has licensed its other 50% shareholder Otsuka Pharmaceutical Factory, Inc. (OPF) to use DIABECELL® in USA and Japan. OPF is further developing the product in USA and DOL retains the right to use it in the rest of the world so is no longer carrying out research and development in New Zealand.

Read More Read Less
Load More

— 1 March 2016

LCT expects crucial Parkinson’s clinical trial results in early 2017

Australasian biotech company Living Cell Technologies says it will know the outcome of a make-or-break clinical trial on its regenerative cell therapy for Parkinson's disease in the first quarter of next year. If the trial succeeds, Living Cell's lead product NTCELL will be the world's first disease-modifying treatment for Parkinson's as existing treatments only deal with the symptoms rather than stopping the degeneration of the brain.

Read More Read Less
Load More
— 16 November 2016

LCT Annual General Meeting. To be held at Sheraton on the Park, 161 Elizabeth Street, Sydney at 10.30am.

Load More
Announcements

— 24 August 2016

Preliminary Final Report

The Preliminary Final Report (Appendix 4E) on the results for the year ended 30 June 2016 is attached. The net loss for the financial year to 30 June 2016 was $3,093,163 compared to a loss of $7,043,402 in the prior year. The decreased loss was primarily due to markedly reduced share of the joint venture loss as the carrying value of the investment has been reduced to zero. The end of year cash balance was $5,301,999 compared to $5,144,027 last year due to the $3.7m raised in the private placements and share purchase plan, partially offset by clinical trial and operating costs.

Read More Read Less

— 22 August 2016

LCT’s joint venture focuses on US development

50% owned joint venture company Diatranz Otsuka Limited (DOL) has licensed its other 50% shareholder Otsuka Pharmaceutical Factory, Inc. (OPF) to use DIABECELL® in USA and Japan. OPF is further developing the product in USA and DOL retains the right to use it in the rest of the world so is no longer carrying out research and development in New Zealand.

Read More Read Less
Load More
LCT in the News

— 1 March 2016

LCT expects crucial Parkinson’s clinical trial results in early 2017

Australasian biotech company Living Cell Technologies says it will know the outcome of a make-or-break clinical trial on its regenerative cell therapy for Parkinson's disease in the first quarter of next year. If the trial succeeds, Living Cell's lead product NTCELL will be the world's first disease-modifying treatment for Parkinson's as existing treatments only deal with the symptoms rather than stopping the degeneration of the brain.

Read More Read Less
Load More
Events
— 16 November 2016

LCT Annual General Meeting. To be held at Sheraton on the Park, 161 Elizabeth Street, Sydney at 10.30am.

Load More